🩺 The evolving role of SBRT in metastatic kidney cancer At the 2nd Florence International Consensus, Prof. Chad Tang from @UTMDAnderson highlights how stereotactic body radiotherapy (SBRT) is becoming an increasingly important part of metastatic renal cell carcinoma (RCC) management. #FlorenceConsensus26 🎯 Oligometastatic disease SBRT may help defer systemic therapy and its associated side effects in selected patients. Local treatment approaches—including radiotherapy, surgery and interventional ablation—offer options that work through mechanisms distinct from systemic therapy. 🔬 Oligoprogressive disease By targeting a limited number of progressing lesions, SBRT may allow patients to remain on their current systemic treatment for longer, potentially delaying the need to switch to subsequent lines of therapy. 💡 The key takeaway: Across the metastatic disease spectrum, SBRT is expanding the role of local treatment in kidney cancer care, supporting more tailored treatment strategies and helping clinicians consider how best to manage disease progression while preserving treatment options. 📍 As evidence and clinical experience continue to evolve, multidisciplinary decision-making remains essential to identifying the patients most likely to benefit. #KidneyCancer @Lucarecco @CarlottaB @RobClarkeLab @JavierCortesMD @curijoey @delmastro_lucia @ALEDIGNUS12 @Prof_Nadia_H @ClareIsacke @reshmajagsi @KaidarOrit @AnnaKirby17 @matteolambe @Icro_Meattini @hoperugo @TanjaSpanic @MassimoDiMaio75 @Silke_Gillessen @DrRanaMcKay @brian_rini @alison_tree @ChadTangMD @DrYukselUrun @MicheleAquilano @GiulioFrancoli1 @DrDanielHeng